Objective To explore the therapeutic effect of dapagliflozin combined with irbesartan on hypertensive dia-betic nephropathy.Methods 100 patients with hypertension combined with diabetic nephropathy who received treat-ment in the Department of Nephrology of Anxi County Hospital from August 2021 to September 2023 were selected as the study objects and divided into the control group and the study group according to the random number table method,with 50 cases each group.The control group was treated with irbesartan+metformin+captopril tablets,and the study group was treated with irbesartan+dapagliflozin.The effects of blood glucose level,renal function index and total incidence of adverse events in the two groups were compared.Results After 2 months of treatment,the fasting blood glucose level(5.69±1.69)mmol/L,2-hour postload plasma glucose level(7.56±1.98)mmol/L and glycated hemo-globin A1c(6.32±0.69)%levels of the study group were lower than those of the control group,and the differences were statistically significant(t=3.404,3.941,10.219,all P<0.05).After 2 months of treatment,the levels of creatinine(62.35±6.98)μmol/L,the level of 24-hour urinary protein quantification(130.49±20.51)mg/24 h and urinary albumin excretion rate(70.45±10.11)μg/min in the study group were lower than those in the control group,and differences were statistically significant(t=7.955,4.349,7.247,all P<0.05).There was no significant difference in the total inci-dence of adverse events between the two groups(P>0.05).Conclusion In the treatment of hypertensive patients with diabetic nephropathy,the combination of dapagliflozin and irbesartan can improve the blood glucose level and renal function indexes.
Diabetic nephropathyHigh blood pressureDapagliflozinIrbesartanBlood glucose levelsRenal func-tion index
NETL
NSTL
万方数据
